KRTX vs. RDY, SRPT, UTHR, VTRS, LEGN, TEVA, CTLT, BGNE, BMRN, and ASND
Should you be buying Karuna Therapeutics stock or one of its competitors? The main competitors of Karuna Therapeutics include Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Viatris (VTRS), Legend Biotech (LEGN), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Karuna Therapeutics (NASDAQ:KRTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.
Karuna Therapeutics presently has a consensus target price of $293.92, suggesting a potential downside of 10.89%. Dr. Reddy's Laboratories has a consensus target price of $80.00, suggesting a potential upside of 9.02%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Karuna Therapeutics.
In the previous week, Dr. Reddy's Laboratories had 2 more articles in the media than Karuna Therapeutics. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 2 mentions for Karuna Therapeutics. Dr. Reddy's Laboratories' average media sentiment score of 1.43 beat Karuna Therapeutics' score of 1.30 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.
14.0% of Dr. Reddy's Laboratories shares are held by institutional investors. 13.2% of Karuna Therapeutics shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Dr. Reddy's Laboratories received 194 more outperform votes than Karuna Therapeutics when rated by MarketBeat users. However, 66.29% of users gave Karuna Therapeutics an outperform vote while only 58.87% of users gave Dr. Reddy's Laboratories an outperform vote.
Dr. Reddy's Laboratories has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
Karuna Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.
Dr. Reddy's Laboratories has a net margin of 19.26% compared to Karuna Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 20.97% beat Karuna Therapeutics' return on equity.
Summary
Dr. Reddy's Laboratories beats Karuna Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Karuna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Karuna Therapeutics Competitors List
Related Companies and Tools